Dextromethorphan/quinidine
Dextromethorphan/quinidine, sold under the brand name Nuedexta, is a fixed-dose combination medication for the treatment of pseudobulbar affect (PBA). It contains dextromethorphan (DXM) and the class I antiarrhythmic agent quinidine.
| Combination of | |
|---|---|
| Dextromethorphan | Sigma-1 receptor agonist, NMDA receptor antagonist, serotonin–norepinephrine reuptake inhibitor |
| Quinidine | Antiarrhythmic agent, CYP2D6 inhibitor |
| Clinical data | |
| Trade names | Nuedexta |
| Other names | AVP-923; DXM/quinidine |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611048 |
| License data | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | dextromethorphan 11%, quinidine 70-80%. Food has no effect on absorption. |
| Metabolism | Liver, extensive. Dextromethorphan is catalyzed by CYP2D6. Quinidine is metabolized by CYP3A4 and competitively inhibits the metabolism of dextromethorphan to increase and prolong plasma concentrations of dextromethorphan |
| Elimination half-life | dextromethorphan 13h, quinidine 7h |
| Excretion | quinidine 5-20% |
| Identifiers | |
| CAS Number | |
| KEGG | |
Dextromethorphan/quinidine was approved for medical use in the United States in October 2010, and is marketed by Avanir Pharmaceuticals.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.